Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels

International Journal of Cancer

Volumn 139, Issue 7, 2016, Pages 1520-1533

  Bonilla, Carolina ^a,b   Lewis, Sarah J ^a,b   Rowlands, Mari Anne ^a   Gaunt, Tom R ^a,b   Davey Smith, George ^a,b   Gunnell, David ^a   Palmer, Tom ^c   Donovan, Jenny L ^a   Hamdy, Freddie C ^d   Neal, David E ^d,e   Eeles, Rosalind ^f,g   Easton, Doug ^h   Kote Jarai, Zsofia ^f   Al Olama, Ali Amin ^h   Benlloch, Sara ^h   Muir, Kenneth ^i,j   Giles, Graham G ^k,l   Wiklund, Fredrik ^m   Grönberg, Henrik ^m   Haiman, Christopher A ⁿ   Schleutker, Johanna ^o,p   Nordestgaard, Børge G ^q   Travis, Ruth C ^d   Pashayan, Nora ^h,r   Khaw, Kay Tee ^s   Stanford, Janet L ^t,u   Blot, William J ^v   Thibodeau, Stephen ^w   Maier, Christiane ^x   Kibel, Adam S ^y,z   Cybulski, Cezary ^aa   Cannon Albright, Lisa ^ab   Brenner, Hermann ^ac   Park, Jong ^ad   Kaneva, Radka ^ae   Batra, Jyotsna ^af   Teixeira, Manuel R ^ag,ah   Pandha, Hardev ^ai   Lathrop, Mark ^aj,ak   Martin, Richard M ^a,b,al   Holly, Jeff M P ^a,al   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF WARWICK   (United Kingdom)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k CANCER EPIDEMIOLOGY CENTRE   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o UNIVERSITY OF TURKU   (Finland)

^p TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^q GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^t Fred Hutchinson Cancer Research Center   (United States)

^u UNIVERSITY OF WASHINGTON   (United States)

^v INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^w MAYO CLINIC   (United States)

^x UNIVERSITY HOSPITAL ULM   (Germany)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

^z WASHINGTON UNIVERSITY   (United States)

^aa POMERANIAN MEDICAL UNIVERSITY   (Poland)

^ab UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^ac GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ad H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^ae MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^af QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^ag PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^ah UNIVERSITY OF PORTO   (Portugal)

^ai UNIVERSITY OF SURREY   (United Kingdom)

^aj CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^ak MCGILL UNIVERSITY   (Canada)

^al UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

ALSPAC; IGFBP3; insulin like growth factor binding proteins; insulin like growth factors; Mendelian randomization; PRACTICAL; prostate cancer; ProtecT; single nucleotide polymorphisms; UKHLS

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CASE CONTROL STUDY; CHROMOSOME 12Q; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC PARAMETERS; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HARDY WEINBERG EQUILIBRIUM; HIGH RISK POPULATION; HUMAN; IGF I GENE; IGF II GENE; IGFBP1 GENE; IGFBP3 GENE; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME;

EID: 84978264652     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30206     Document Type: Article

References (47)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8:915–28.
2. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149:461–71.
3. Rowlands M-A, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009; 124:2416–29.
4. Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque M-D, Cook MB, Deschasaux M, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res, in press.
5. Rowlands M-A, Holly JMP, Gunnell D, et al. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res 2012; 72:503–15.
6. Neuhouser ML, Platz EA, Till C, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res 2013; 6:91–9.
7. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003; 63:3991–4.
8. Young NJ, Metcalfe C, Gunnell D, et al. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)−2, and IGFBP-3 in men in the United Kingdom. Cancer Causes Control 2012; 23:907–17.
9. Kristal AR, Stanford JL. Cruciferous vegetables and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13:1265
10. Rowlands M-A, Holly JMP, Gunnell D, Gilbert R, Donovan J, Lane JA, Marsden G, Collin SM, Hamdy F, Neal DE, Martin RM. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control 2010; 21:1842.
11. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk-interpreting the evidence. J Natl Cancer Inst 1998; 90:876–9.
12. Davey Smith G, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32:1–22.
13. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23:R89–98.
14. Li Y, Willer CJ, Ding J, et al. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34:816–34.
15. Boyd A, Golding J, Macleod J, et al. Cohort Profile: the “children of the 90s”–the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 2013; 42:111–27.
16. Fraser A, Macdonald-Wallis C, Tilling K, et al. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 2013; 42:97–110.
17. Bonilla C, Ness AR, Wills AK, et al. Skin pigmentation, sun exposure and vitamin D levels in children of the Avon Longitudinal Study of Parents and Children. BMC Public Health 2014; 14:597
18. Jeffreys M, Northstone K, Holly J, et al. Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case–control study. Cancer Causes Control 2011; 22:945–53.
19. Delaneau O, Marchini J. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat Commun 2014; 5:3934
20. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5:e1000529
21. Howie B, Fuchsberger C, Stephens M, et al. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44:955–9.
22. Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL consortium. Cancer Epidemiol Biomarkers Prev 2008; 17:2052–61.
23. Amin Al Olama A, Kote-Jarai Z, Berndt SI, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46:1103–9.
24. Lawlor DA, Harbord RM, Sterne JAC, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27:1133–63.
25. von Hinke Kessler Scholder S, Davey Smith G, Lawlor DA, et al. Mendelian randomization: the use of genes in instrumental variable analyses. Health Econ 2011; 20:893–6.
26. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015 ;btv402.
27. Angrist JD, Krueger AB. The effect of age at school entry on educational attainment: an application of instrumental variables with moments from two samples. J Am Stat Assoc 1992; 87:328–36.
28. Inoue A, Solon G. Two-sample instrumental variable estimators. Rev Econ Stat 2010; 92:557–61.
29. Petry CJ, Ong KK, Barratt BJ, et al. Common polymorphism in H19 associated with birthweight and cord blood IGF-II levels in humans. BMC Genet 2005; 6:22
30. Terry KL, Tworoger SS, Gates MA, et al. Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis 2009; 30:2042–6.
31. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012; 21:223–42.
32. Kaplan RC, Petersen A-K, Chen M-H, et al. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet 2011; 20:1241–51.
33. Holly JMP, Perks CM. Insulin-like growth factor physiology: what we have learned from human studies. Endocrinol Metab Clin North Am 2012; 41:249–63.
34. He Y-H, Lu X, Yang L-Q, et al. Association of the insulin-like growth factor binding protein 3 (IGFBP-3) polymorphism with longevity in Chinese nonagenarians and centenarians. Aging (Albany NY) 2014; 6:944–51.
35. Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell 2015; n/a–n/a.
36. Cao Y, Nimptsch K, Shui IM, et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer 2015; 136:2418–26.
37. Nam RK, Zhang WW, Trachtenberg J, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:1429–37.
38. Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 2006; 98:123–34.
39. Schumacher FR, Cheng I, Freedman ML, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010; 19:3089–101.
40. Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17 SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 2008; 305:296–305.
41. Tsuchiya N, Wang L, Horikawa Y, et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 2005; 26:225–31.
42. Qian J, Zhou H, Chen J, et al. Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population. PLoS One 2014; 9:e85609
43. Hernandez W, Grenade C, Santos ER, et al. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 2007; 28:2154–9.
44. Park K, Kim JH, Jeon HG, et al. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urology 2010; 75:1516.e1–7.
45. Johansson M, McKay JD, Rinaldi S, et al. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate 2009; 69:1281–91.
46. Gu F, Schumacher FR, Canzian F, et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:2877–87.
47. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013; 178:1177–84.